Date: 2014-02-28
Type of information: Private placement
Company: Compugen (Israel)
Investors:
Amount: $72.5 million
Funding type:
Planned used:
Others: * On March 5, 2014, Compugen has announced that it has closed its underwritten public offering of 6,900,000 ordinary shares, including 900,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $10.50 per share. Gross proceeds to Compugen are approximately $72.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen.
* On February 28, 2014, Compugen has announced that it has priced an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $10.50 per share. Gross proceeds to Compugen are expected to be $63 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen. The offering is expected to close on or about March 5, 2014, subject to satisfaction of customary closing conditions. Compugen has granted the underwriters a thirty day option to purchase up to 900,000 additional ordinary shares.
Jefferies LLC is acting as the sole bookrunner for the proposed offering. JMP Securities LLC, Oppenheimer & Co. Inc. and Chardan Capital Markets are acting as co-managers.
Therapeutic area:
